Roivant Sciences (ROIV) Non Operating Investment Income (2020 - 2025)

Roivant Sciences has reported Non Operating Investment Income for 6 years, with the latest figure at $21.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non Operating Investment Income rose 201.3% year-over-year to $21.6 million; the trailing twelve-month figure through Dec 2025 stood at $109.7 million (up 244.61% YoY), and the FY2026 full-year result was $105.0 million, up 90.35% from the prior year.
• Non Operating Investment Income for Q4 2025 stood at $21.6 million, down from $128.5 million in the prior quarter.
• The five-year high for Non Operating Investment Income was $443.8 million in Q3 2021, with the low at -$54.7 million in Q3 2022.
• Historically, Non Operating Investment Income has averaged $30.2 million across 5 years, with a median of -$8.6 million in 2021.
• Annual changes were most pronounced in 2024 — Non Operating Investment Income soared 301.3% — and 2025, when it slumped 225.61%.
• Roivant Sciences' Non Operating Investment Income stood at -$38.0 million in 2021, then soared by 168.22% to $25.9 million in 2022, then plunged by 140.34% to -$10.5 million in 2023, then slumped by 103.63% to -$21.3 million in 2024, then soared by 201.3% to $21.6 million in 2025.
• The last three Non Operating Investment Income figures came in at $21.6 million (Q4 2025), $128.5 million (Q3 2025), and -$19.1 million (Q2 2025), per Business Quant data.